Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Cellebrite DI Ltd

IQV vs. CLBT: Which Stock Is the Better Value Option?

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient fo

Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentati

IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc's third-party validation demonstrates that IQVIA's DCT program processes personal data i

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

CrowdStrike

Diamondback Energy

GlobalFoundries

Spotify

Visa

Amid fears of persistent inflation and economic slowdown, many growth names, especially those that aren't yet profitable, have fared poorly this year. However, growth stocks tend to outperform the broader market over the long term.

The 7 Best Growth Stocks to Buy in October

IQVIA Holdings Inc. bottomed on June 16 and has since rallied 28% in a breakout attempt that finally failed. IQVIA Holdings stock is a strong leader in its industry, and despite some recent weakness, has significantly outperformed the broader healthcare sector.

IQVIA: Rebound Is Likely But Downtrend Is Still Intact (Technical Analysis)

IQVIA's (IQV) enormous treasure trove of information is a distinguishing asset.

Here's Why a Hold Strategy is Apt for IQVIA (IQV) Stock

Amazon

Alexandria Real Estate Equities

Bath and Body Works

Salesforce

Catalent

Caesars Entertainment

Alphabet

Labcorp Holdings Inc

Microsoft

ServiceNow

Teradyne

Wall Street analysts follow S&P 500 stocks more closely than almost anyone. But even they get it wrong sometimes, too.

Analysts Totally Blow It On 12 Gutsy Stock Recommendations

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors. With one of the first fact-based examinations of the return on investment of DCTs, IQVIA offers tangible data that can help sponsors calculate the overall benefit of bui

New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2022 Global Healthcare Conference in New York City on Wednesday, September 14, 2022 at 2:35 p.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is

IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 13, 2022 at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. Abou

IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced it has been named the 2022 Marketplace Healthcare and Life Sciences Partner of the Year by Snowflake, the Data Cloud company. IQVIA was recognized for its achievements in leveraging the Snowflake Data Cloud for IQVIA's Data-as-a-Service (DaaS) solution, giving customers quick access to searchab

IQVIA Wins Snowflake's “Marketplace Healthcare and Life Sciences Partner of the Year” Award

Reasons to Retain IQVIA Holdings (IQV) Stock in Your Portfolio

Earnings quality and resiliency were on full display last quarter for IQVIA. The company continues to compound FCF at a long-term geometric average of 23%, with equally as high FCF ROE.

IQVIA: Resiliency And Quality Never Left, Q2 Earnings Evidence The Same

Agilent Technologies

Cadence Design Systems

Global X Thematic Growth ETF

Invesco Select Growth ETF

Paychex

Synopsys

These are the best growth stocks to buy on the dip. A, CDNS, GXTG, IVSG, IQV, PAYX, and SNPS are poised to deliver impressive returns.

7 Growth Stocks to Buy on the Dip

IQVIA's (IQV) second-quarter 2022 earnings and revenues surge year over year.

IQVIA (IQV) Beats on Q2 Earnings & Revenues, Alters '22 View

IQVIA Holdings Inc. (NYSE:IQV ) Q2 2022 Earnings Conference Call July 21, 2022 9:00 AM ET Company Participants Ari Bousbib - Chairman, Chief Executive Officer Ron Bruehlman - Executive Vice President, Chief Financial Officer Mike Fedock - Senior Vice President, Financial Planning and Analysis Nick Childs - Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Sandy Draper - Guggenheim Eric Coldwell - Baird Elizabeth Anderson - Evercore Derik de Bruin - Bank of America David Windley - Jefferies Jack Meehan - Nephron Research Adam - Stifel Tejas Savant - Morgan Stanley John Sourbeer - UBS Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA second quarter 2022 earnings conference call.

IQVIA Holdings (IQV) CEO, Ari Bousbib on Q2 2022 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2022. Second-Quarter 2022 Operating Results Revenue for the second quarter of $3,541 million increased 3.0 percent on a reported basis and 7.1 percent at constant currency compared to the second quarter of 2021. T

IQVIA Reports Second-Quarter 2022 Results

IQVIA Holdings' (IQV) second-quarter 2022 earnings and revenues are likely to have risen year over year.

What's in the Offing for IQVIA Holdings (IQV) in Q2 Earnings?

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IQVIA Holdings (IQV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2022 financial results before the market opens on Thursday, July 21, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slid

IQVIA to Announce Second-Quarter 2022 Results on July 21, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced the company has been named a Leader in the IDC MarketScape: Worldwide Life Science Sales and Marketing IT Outsourcing Services 2022 Vendor Assessment (doc #US41808017, March 2022). The report noted IQVIA's deep life sciences domain expertise, global skilled workforce, and breadth of i

IQVIA Recognized as a Leader in Life Science Sales and Marketing IT Outsourcing Services

Biogen

Illumina

These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead.

3 Biotech Stocks to Sell Now

AppLovin Corp

IQV vs. APP: Which Stock Is the Better Value Option?

IQV vs. APP: Which Stock Should Value Investors Buy Now?

BioNTech SE

Gilead Sciences

Halozyme Therapeutics

Moderna

United Therapeutics

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.

News for IQVIA Hlds Stock (IQV)